Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (07/21/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Adult Acute Lymphoblastic Leukemia (ALL)

Revised text of treatment option in Table 2 for recurrent ALL to include blinatumomab.

Treatment for Recurrent Adult ALL

Revised text in treatment option to add blinatumomab to reinduction chemotherapy.

Added Blinatumomab as a new subsection.

Added text to treatment options under clinical evaluation to include chimeric antigen receptor T-cell therapy (cited Maude et al. as reference 11).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment for Recurrent Adult ALL

Next section >
About This PDQ Summary